Skin Diseases
12
Pipeline Programs
3
Companies
4
Clinical Trials
9
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
10
Early DiscoveryClinical DevelopmentMarket
On Market (9)
Approved therapies currently available
U
CUBICINApproved
daptomycin
Unknown Companyintravenous2003
U
CUBICIN RFApproved
daptomycin
Unknown Companyintravenous2003
Competitive Landscape
3 companies ranked by most advanced pipeline stage
GSKLONDON, United Kingdom
2 programs1
Fluticasone propionatePhase 41 trial
Substance PN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
GSKFluticasone propionate
AstraZenecaDaptomycin
BeOne MedicinesBG-A3004
GSKSubstance P
Clinical Trials (4)
Total enrollment: 502 patients across 4 trials
A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis
Start: Dec 2013Est. completion: Feb 2015107 patients
Phase 4Completed
China Registration Study in Patients With Skin Infections
Start: Sep 2008Est. completion: Sep 2010265 patients
Phase 3Completed
A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
Start: Mar 2026Est. completion: Aug 202898 patients
Phase 1Not Yet Recruiting
Substance P Challenge in Healthy Participants
Start: Mar 2021Est. completion: Jul 202132 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space